Scinai Immunotherapeutics Ltd. Publishes Peer-Reviewed Data on PC111's Disease-Modifying Potential
July 29th, 2025 1:38 PM
By: Newsworthy Staff
Scinai Immunotherapeutics Ltd. has published peer-reviewed data in the Journal of Dermatological Treatment, showcasing PC111's potential as a disease modifier for pemphigus and SJS/TEN, offering a non-immunosuppressive treatment approach.
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) announced the publication of peer-reviewed data in the Journal of Dermatological Treatment, highlighting the disease-modifying potential of PC111, a first-in-class human anti-Fas Ligand monoclonal antibody. The study demonstrated PC111's ability to prevent blister formation in humanized models of pemphigus by targeting soluble Fas Ligand, presenting a non-immunosuppressive treatment option. Additionally, the data suggested potential applications in treating Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), a severe dermatological condition. CEO Amir Reichman emphasized the significance of these findings, noting PC111's potential to revolutionize treatment for these conditions with high unmet medical needs and to create value for both patients and shareholders. For further details, visit https://ibn.fm/grLYD.
Source Statement
This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,
